Cognitive Bias, Diagnostic Error, and Treatment Pitfalls in Dermatology

Conclusions

• Diagnostic anchoring on an initial referral diagnosis can cause clinicians to miss the true cause of a rash and stop the wrong medication.
• A thorough history, full exam, and early differential diagnosis are essential before committing to a treatment path.
• Premature closure and escalation of commitment can prolong patient suffering when a worsening case is not re-evaluated.
• Worsening on a biologic or other advanced therapy should be treated as a red flag that prompts reconsideration and often stopping the drug.
• Even expert pathology opinions are only data points, and the treating clinician must integrate them with the full clinical picture.
• Rare diagnoses should not be favored over common conditions simply because they are memorable or recently encountered.
• Simple bedside tests and basic investigations can prevent months of unnecessary immune-modulating therapy.
• Logical fallacies such as false dichotomy, omission bias, loss aversion, appeal to the masses, and appeal to authority can distort dermatologic treatment decisions.
• Risk assessment should be individualized by considering comorbidities, disease mechanism, route, burden, and the actual frequency and severity of adverse events.
• Fear of adverse effects can lead to undertreatment, so clinicians should balance safety concerns against the harms of leaving disease uncontrolled.
• The therapeutic middle ground, including conventional systemic agents, phototherapy, and topicals, is often an effective and lower-risk starting point.
• Metacognition, humility, and openness to revising the diagnosis are central to avoiding cognitive bias and improving patient outcomes.